https://www.selleckchem.com/pr....oducts/cobimetinib-g
Limitations in AI-segmentation correlated to cases where AI model training was lacking. The five first treated patients complied well with the median adaptive procedure duration of 17.6min (from CBCT acceptance to treatment delivery start). The treated bladder patients demonstrated a 42% median primary PTV reduction, indicating a 24%-30% reduction in V to the bowel cavity, compared to non-ART. A novel commercial oART solution was demonstrated feasible for various pelvic sites. Clinically acceptable AI-segmentation an
Like
Comment
Share
